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The COPD Biomarkers Qualification Consortium (CBQC) is a public-private partnership formed in 2010 with a 
goal of qualifying biomarkers and clinical assessment tools for use in clinical or nonclinical decision-making and 
particularly within the regulatory context.
The St George’s Respiratory Questionnaire (SGRQ) is a measure of health-related quality of life widely used in 
clinical research. The aim of the CBQC working group on SGRQ was to construct an individual patient level 
database of clinical trial data that included the SGRQ, to use this to confirm the reliability and validity of the SGRQ 
as an outcome measure of health status, and investigate its use as a predictor of future events (exacerbations 
and mortality). This manuscript describes the formulation of the CBQC database and presents the baseline 
demographic and clinical characteristics of the integrated SGRQ database overall, and by study type (short-term 
[≤1 year], medium-term [2-4 years] and observational studies).
Distribution of baseline SGRQ scores varied little by demographic determinants except for income region in 
the observational data set (low-middle income countries +10 units compared with high income, p<0.0001) and 
this observation held across studies. SGRQ scores increased with increasing modified Medical Research Council 
dyspnea scores (mean differences ranged 6.9-17.9 units) and with increasing airflow limitations (Global initiative 
for chronic Obstructive Lung Disease grades 1 to 4; differences ranged 4.5-16.1 units), consistent across study 
types.
As a method of cross-sectional comparison, the SGRQ appears to be relatively free of bias from demographic 
factors although care should be taken when making cross sectional comparisons of scores between patients in 
countries at different levels of socio-economic development.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a 
serious public health issue, recognized by the World 
Health Organization (WHO) and is currently the third 
leading cause of death in the United States.1 COPD 
impacts a patient’s health status across the full range 
of activities of living from self-care to social and family 
interactions and occupation.2,3 Current therapy for 
COPD is focused on improving lung function and 
reducing inflammation, thereby reducing symptoms and 
improving both functionality and health-related quality 
of life (HRQL).4 This is currently achieved through the 
use of long-acting bronchodilators which are commonly 
used in combination with inhaled corticosteroids. The 
development of novel therapies for COPD may target 
new mechanisms of action and provide an opportunity 
for more personalized care.4 To fully evaluate novel 
mechanisms, a wider range of recognized regulatory 
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endpoints and biomarkers are required. 
The COPD Biomarkers Qualification Consortium 
(CBQC) is a public-private partnership which was 
formed following a workshop held in January 2010 and 
hosted by the COPD Foundation. The workshop brought 
together researchers and regulators to discuss the 
potential for formalizing new endpoints and biomarkers 
for use in the development of treatments for COPD. The 
formation of the consortium and its aims are detailed 
elsewhere.5 Consortium membership includes the 
COPD Foundation, the National Institutes of Health, 
academic researchers and several pharmaceutical 
companies and has the aim of qualifying clinical 
endpoints for use in drug development. The CBQC 
also works with specialist research organizations to 
both build and verify the database and to develop and 
perform analyses to support these aims (Figure 1). 
The goal of the CBQC is to qualify biomarkers and 
clinical assessment tools for specific contexts of use 
which define how a particular biomarker will be used 
in clinical or nonclinical decision-making and within 
the regulatory framework for the development of new 
medicines. Recognized contexts of use may include 
stratification of patient populations, use in dose ranging 
studies in earlier medicine development and as outcome 
measures in regulatory clinical trials. The initial 
approach of the CBQC was to source and combine large 
clinical datasets from the pharmaceutical industry and 
publicly available sources. The first working groups of 
the consortium were formed based on the output from 
the January 2010 meeting. Participating companies, 
AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline 
and Novartis, have contributed patient level data 
from clinical trial datasets and observational studies. 
Publicly available data sources such as the National 
Emphysema Treatment Trial (NETT) and COPD 
Genetic Epidemiology (COPDGene) data have also 
been integrated into the CBQC database. Since not all 
studies include all the endpoints under consideration, 
each working group of CBQC draws only on the relevant 
studies for analysis.
The CBQC database therefore aggregates data from 
selected randomized clinical trials and observational 
studies to advance knowledge of clinical measures 
used in management of COPD patients (Table 1). 
Health status, measured by the St George’s Respiratory 
Questionnaire (SGRQ), was one of the initial measures 
evaluated in this way, along with fibrinogen6,7 and the 
6-minute walk test (6MWT).8
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The SGRQ is a 50-item patient-reported outcome 
measure that was designed to assess health-related 
quality of life in patients with chronic airflow 
limitation.9,10 Specifically, the instrument was 
developed to evaluate the impact of airflow limitation 
on the patient’s life in terms of symptoms, daily activity 
limitation, and psychosocial well-being. The SGRQ-C is 
a COPD specific, 40-item version of the original SGRQ 
and was derived following detailed analysis of data from 
large studies in COPD.11 The SGRQ and SGRQ-C are 
divided into 2  major components: Part I produces the 
Symptoms score, while Part 2 produces the Activity 
and Impacts scores; a total score is also generated. The 
scoring method used for both versions of the SGRQ 
provides equivalent SGRQ scores, i.e., a score range 
from 0 (best health status) to 100 (worst health status).
Several clinical studies, as well as several large 
population-based observational studies, have included 
the SGRQ as a measure of health status. Although the 
United States Food & Drug Administration has indicated 
acceptance of the SGRQ as an outcome measure for 
clinical trials of COPD,12 the SGRQ has until recently 
only been included in product labels for monotherapy 
bronchodilator treatments for COPD using placebo as a 
comparator. There remained a need for further analyses 
of large prospective studies to confirm the performance 
properties of the SGRQ total score, specifically in 
terms of cross-sectional validity and 
to describe longitudinal patterns 
and trajectories of change and 
predictive validity as an indicator 
of disease progression, morbidity, 
and mortality. As these analyses 
involved the pooling of anonymized 
data, National Health Service ethics 
approval and institutional review 
board approval were not required. 
Appropriate approvals and written 
informed consent had been obtained 
originally for all the included studies.
The objective of this manuscript is 
to describe the baseline demographic 
and clinical characteristics of the 
integrated SGRQ database overall, 
and by study type. In addition, to 
describe SGRQ scores within and 
across study types by baseline 
characteristics.
Methods
Minimum data requirements were created based on an 
analysis plan which addressed the study objectives of 
the working group set out above.  A total of 20 eligible 
studies were entered in the database for analysis, aiming 
to balance the geographic spread of the patients, the 
duration of studies and the numbers of patients included 
from each participating company, while maintaining the 
required minimum data requirements for the analysis 
(Figure 2). NETT, a 5-year randomized, controlled trial 
evaluating the effectiveness of lung volume reduction 
surgery, was analyzed separately due to the specialist 
nature of the data which could not be meaningfully 
combined into the SGRQ integrated dataset. Additional 
studies were considered, but excluded based on study 
design and development phase, number of patients 
included, and publication date (all included studies 
were published during or after 2003). COPD diagnosis 
and severity was defined by the studies included in 
the database. The incorporated studies covered a wide 
range of COPD severity, as defined by lung function 
and including measures of reversibility. Details of 
the included studies are provided in the online data 
supplement, Table S1. 
Data were provided to a third-party database provider, 
INC Research, by each company for data entry (Figure 2). 
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Under the consortium agreement, all data were entered 
by a third party and comparisons were only made at 
the level of drug class during analysis. The database 
was provided to Evidera, a company specializing in 
outcomes analytics, for quality control checks and 
subsequent analysis. Following receipt of the data 
from INC Research, Evidera mapped and reconciled 
all variables from each study so that they might be 
analyzed as a single dataset. This involved review of 
each variable in each study in the context of how the 
variable was operationalized, and then manipulation 
of the variable so that studies could subsequently be 
analyzed together in the full database. In addition, some 
variables were derived upon receipt of the database (i.e., 
study drop-out status), as they were relevant for analysis 
but were not calculated in the data files transferred.
This quality control process was designed to ensure 
the accuracy of the data for subsequent analyses. 
An iterative process was developed and individually 
applied to each study dataset. Baseline descriptive 
demographic and clinical characteristics were tabulated, 
as well as available longitudinal measures (SGRQ, 
6MWT, forced expiratory volume in 1 sec [FEV1]), and 
medical-related events tables from each individual 
study. Logic checks were then conducted to ensure 
that these variables were within a feasible predefined 
range, (e.g., SGRQ scores were all between 0 and 100), 
and that the values appeared reasonable based on the 
study design and the disease severity of the enrolled 
COPD population. These descriptive tables were then 
compared to a primary publication for each study. 
Where discrepancies were found, individual study 
sponsors were contacted to reconcile identified issues 
or discrepancies. Following this step each study sponsor 
completed and signed a review form documenting their 
review and any discrepancies they may have identified, 
and then emailed this form to Evidera. Any outstanding 
issues were then resolved with assistance from the 
sponsor, the data integration company (INC Research), 
or the SGRQ working group, as necessary.
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A total of 20 studies were available for 
analysis in the SGRQ aggregated database: 
17 randomized controlled trials (RCTs) 
and 3 observational studies (ECLIPSE 
[Evaluation of COPD Longitudinally to 
Identify Predictive Surrogate Endpoints],13 
n=2084; COPDGene,14 n=4410; and Body 
mass index-airway Obstruction-Dyspnea-
Exercise performance [BODE],15 n=1006) 
(Figure 2). The 17 RCTs were grouped by 
study duration, categorized as short-term 
(≤1-year duration), comprising 14 trials 
with 14,814 participants, and medium-
term (2-4 years’ duration) comprising 3 
trials with 12,043 participants. Further 
details of each included study are provided 
in the online data supplement Table S1.
The mean age in the integrated database 
was 64.1, and age was similar across all 
study types (Table 2). Mean BMI in the 
integrated dataset was 26.3 kg/m2, and 
was also fairly consistent across the 3 
study types. Observational studies had 
more females (37%) than either of the 
short- (29%) or medium-term (24%) clinical 
trial datasets, and mean FEV1 % predicted 
was higher in observational studies 
(53.3%) compared with the short- (47.2%) 
and medium-term trials (45.0%). Dyspnea, 
measured at baseline by modified Medical 
Research Council dyspnea grade (mMRC) 
and defined as a score ≥2, was reported by 
63.6% of patients in the integrated dataset, 
with higher rates in the short-term trials 
(69.7%), relative to both the medium-term 
trials (59.9%) and observational (59.6%) 
Results
Multivariate regression models were conducted to 
evaluate relationships between baseline SGRQ and 
demographic and clinical characteristics, with baseline 
SGRQ total score as the dependent variable, and the 
following as covariates: gender, age, 
race (white/non-white), categorical body 
mass index (BMI), WHO classification of 
region and income, study type (short-term, 
medium-term, observational), year study 
began, and smoking status (current/past).
study populations.  Data on history of cardiovascular 
disease (including hypertension) were missing for over 
80% of patients in short-term trials, whereas the majority 
of these data were available for medium-term trials and 
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observational studies, yet the percentage of patients 
reported as experiencing a cardiovascular event was 
very similar for these 2 populations (27% and 29%, 
respectively). 
The mean baseline SGRQ score in the integrated 
database was 46.3, and scores were higher (worse health 
status) in both clinical trial populations (short-term = 
47.3, medium-term = 47.8) relative to the observational 
study population (41.8) (Table 2). The integrated 
database included a wide geographical distribution of 
patients, with more patients from low-middle income 
countries in both the short- (35.5%) and medium-term 
(31.0%) trials compared with the observational studies 
(6.5%).
As expected the mean number of exacerbations 
reported in the 12 months prior to study initiation 
varied considerably by study type as this variable is 
driven by study design and inclusion/exclusion criteria. 
Exacerbation data, collected either as an endpoint or as 
adverse event data were available only in 60% of short-
term trials, 51.3% of medium-term trials, and 86.6% of 
the observational population. Among patients that had 
exacerbation data available, annual exacerbation rates 
ranged from 0.64 (short-term trials) to 1.59 (medium-
term trials). 
Across the 3 study types, distribution of baseline 
SGRQ score varied little by demographic determinants 
(Figure 3). For the demographic determinants analyzed, 
WHO income region was the only factor where a 
difference in SGRQ score between groups at baseline 
exceeded the 4-unit minimum clinically important 
difference, observed in the observational population 
only (low-middle income countries +10 units compared 
to high income), p<0.0001. Small and non-significant 
differences were seen in the baseline SGRQ scores based 
on smoking status, gender and age, dependent on study 
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population and design. Although current smokers, 
women and younger patients (aged 41-60 years) 
reported slightly higher baseline SGRQ scores than ex-
smokers, men and older patients, these differences were 
not significant and were not consistent across all study 
types. 
Disease-related determinants were related to 
baseline SGRQ score with scores increased in line with 
increasing mMRC dyspnea score and with declining 
lung function when defined by Global initiative for 
chronic Obstructive Lung Disease (GOLD)4 grade of 
airflow limitation (1 to 4), and this was consistent across 
study types (Figure 4). These differences ranged from a 
mean of 6.9-17.9 units for mMRC dyspnea score and a 
mean of 4.5-16.1 units for GOLD grade. The presence 
of comorbid cardiovascular disease was also associated 
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with a +5-point higher baseline SGRQ score in the 
observational population, compared with +3.1 and +0.6 
in the medium-term and short-term trials respectively. 
BMI showed a U-shaped relationship with SGRQ score 
across all study types, with higher SGRQ scores at the 
extremes of the reported BMI range.
Baseline SGRQ score and FEV1 percent predicted 
were poorly correlated in the interventional studies 
(Short-term: r = -0.28; Medium-term: r = -0.26); a stronger 
relationship was seen in the Observational data set (r= 
-0.53) (Figure 5). Longitudinally, for the integrated 
dataset, the correlation between change in SGRQ and 
FEV1 percent predicted change, r ranged from 0.10-
0.27 across treatment classes (placebo, long-acting 
bronchodilators and inhaled corticosteroid/long-acting 
beta2-agonist) and follow up time between 3 and 36 
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months. The correlation between change in SGRQ and 
transition dyspnea index over a similar time period (up 
to 24 months) and for the same treatments (but not 
identical studies) was 0.31-0.47.
Discussion
The combination of RCTs and observational studies in 
the CBQC database enables analysis of baseline SGRQ 
scores over a wide variety of demographic and disease-
related determinants by providing access to data from 
patients with a range of disease severity. As expected, 
baseline SGRQ scores varied by mMRC score, and 
GOLD grade. There were differences between different 
demographic groups, but these were generally small 
(less than the 4-unit minimum clinically important 
difference for the SGRQ) and not consistent between 
studies. For example, in the RCTs, smokers had higher 
scores than former smokers and women were higher 
than men, but these differences were not seen in the 
observational studies. There was no consistent effect of 
age across the different types of study either.
The variation in score attributable to socio-economic 
status seen in the observational studies is noteworthy 
since it was large. Specifically, patients in low-medium 
income countries had mean scores that were high (>50 
units) and on average >10 units higher than those in 
high income countries, but this differed from the picture 
seen in the clinical trials, both short- and medium-term. 
The reason for this is not clear, but may be due to an effect 
of standardized inclusion criteria for patients recruited 
to trials that could have minimized the inclusion of 
patients with very poor health status. When considering 
the data from the observational studies in this context, 
it is important to appreciate that only 1 low-medium 
income country (Venezuela) contributed patients, this 
was in the BODE cohort.15 All other patients in BODE 
and the other 2 observational studies came from high 
income countries. While it is possible that the difference 
seen in Venezuela was due to language, another cohort 
study from 6 western-European countries, that included 
Spain, showed quite small differences in mean SGRQ 
scores between them.16 It is not possible to draw any 
firm conclusions about income and SGRQ score based 
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on data from 1 country, and the absence of a similar 
pattern in the RCTs suggests that income may not be an 
important determinant of disease-specific health status 
score. Neither cardiovascular comorbidity nor baseline 
BMI measurement had a large impact on baseline SGRQ 
score, so overall it appears that demographic influences 
on SGRQ score are small, which is important when 
translating the results of studies into clinical practice 
and for more naturalistic or observational study designs 
which may recruit from a wider pool of patients. The poor 
correlation between baseline SGRQ score and FEV1 
percent predicted seen in the RCTs was expected and 
has been reported often before, however the stronger 
correlation in the observational studies is notable and 
is probably due to the much wider range of FEV1 values 
in the participants in these studies, a clear proportion 
of whom had FEV1 values above 80% predicted (i.e., 
in the normal range). There are few reported data in 
individuals with this degree of airflow limitation (or 
none) so this observation is relatively novel.
Conclusions
As a method of cross-sectional comparison, the SGRQ 
appears to be relatively free of bias from demographic 
factors. Care should be taken in cross-sectional 
comparison of scores between patients in countries at 
different levels of socio-economic development.
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